Ducentis BioTherapeutics

Ducentis Biotherapeutics is a preclinical-stage biotechnology company dedicated to developing new treatments for patients with autoimmune diseases. Founded in 2015 by Dr. Philip Huxley, Professor David Blackbourn, and Dr. Rebecca Ashfield, the company aims to explore the potential of the CD200 pathway in controlling unwanted or exaggerated immune responses. Compared with conventional immunomodulators that utilize blocking mechanisms, such as cytokine blockade, CD200R agonists offer a conceptually distinct mechanism of action by specifically targeting overactive immune cells and restoring homeostasis.